National Cancer Center

Japan Health Sciences Foundation

Transgenic Inc.

President, National Cancer Center

Setsuo Hirohashi

Tesshi Yamada

Kazufumi Honda

Miki Shitashige

Masaya Ono

Hiroshi Nose

Tomoyo Hashiguchi

Yosuke Makuuchi

The present invention provides an antibody, which reacts with a FGA or FGA partial peptide in which a part of prolines in the molecule thereof are hydroxylated, and which does not react with an unmodified FGA or FGA partial peptide.

High specificity monoclonal antibody against a protein or a polypeptide having oxidative modification

The screening method for an anticancer drug comprises selecting a compound which blocks the kinase activity of TNIK, or blocks the combination of TNIK with &#x3b2;-catenin/TC4 transcription complex.

Screening method for anticancer drug

A novel protein and a fragment thereof useful as a tumor marker of pancreatic cancer are disclosed. This protein or a fragment thereof is a modified &#x3b1;-fibrinogen protein containing an oxidized amino acid residue(s) or a fragment thereof containing said oxidized amino acid residue(s). The oxidized amino acid residue(s) is one or more amino acid residues selected from the group consisting of (a) a proline residue corresponding to the proline residue at the position of 530 in SEQ ID NO: 2, and (b) a proline residue corresponding to the proline residue at the position of 565 in SEQ ID NO: 2.

Tumor marker for pancreatic cancer

Growing community of inventors

Tokyo, Japan

Setsuo Hirohashi